Weight loss jabs Wegovy: the facts behind the headlines

The biggest misconception: Wegovy is just a shortcut, not a real medicine

One of the most common things people hear about weight loss jabs is that they are a cosmetic fix or a lazy option. That framing misrepresents both the medicine and the condition it treats. Obesity is a chronic health condition shaped by biology, hormones and genetics — not a willpower gap. If you want a full overview of how it works and what to expect, the Wegovy weight loss jab page covers the medicine in detail. Wegovy works by activating GLP-1 receptors in the brain and gut, signalling fullness, reducing appetite and slowing gastric emptying. It does not burn fat independently of diet; it changes the hormonal environment that drives hunger in the first place.

The evidence base is substantial. In the STEP 1 trial (a 68-week study published in the New England Journal of Medicine) adults taking 2.4mg semaglutide weekly lost an average of around 15% of body weight compared with roughly 2.4% in the placebo group. That is the kind of result that takes years of dieting for most people to approach, if they reach it at all. For many, the biological pull back toward a higher weight is simply stronger than any structured programme can overcome on its own. The clinical profile of semaglutide explains the mechanism in more detail if you want to read further.

This is not to say Wegovy is right for everyone, or that it replaces lifestyle change. It is a prescription medicine used alongside a reduced-calorie diet and increased physical activity. A prescriber weighs up your full health picture before recommending it.

Who can actually get these weight loss jabs on a prescription

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, or prediabetes. Lower thresholds can apply for some ethnic backgrounds under UK guidance. BMI alone does not settle the matter; contraindications, current medicines and medical history all form part of the assessment.

NICE recommends semaglutide for weight management only within specialist services, for a maximum of two years, and only where other criteria are met, so NHS access remains limited and waiting lists are long in most areas. Finding out where to access Wegovy in the UK covers both the NHS route and the private prescription route in full. People who do not meet the current NHS criteria, or who prefer not to wait, can access treatment through a regulated private pharmacy following a clinical consultation.

Pregnancy, breastfeeding, and trying to conceive are contraindications. Wegovy is not licensed for anyone under 18. If you have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, or a history of pancreatitis, you would need to discuss this with your prescriber before starting.

What the dose schedule looks like in practice

Wegovy injections follow a structured titration pathway. Treatment starts at 0.25mg weekly (a tolerability level while your system adjusts) and moves up through 0.5mg, 1.0mg and 1.7mg before reaching the 2.4mg maintenance dose. Each step typically lasts around four weeks, and the pace is set by your prescriber, not by how quickly you want to progress. Rushing the schedule is the most common reason for avoidable nausea.

The injection itself goes into the fatty tissue of the abdomen, thigh or upper arm, rotated with each dose. Most people keep their pen in the fridge door alongside everyday things and simply pick a consistent day of the week that fits their routine. A practical guide to Wegovy jabs covers injection technique and site rotation if that detail is useful.

In April 2026 the MHRA approved a single-dose 7.2mg pen (a higher maintenance option for adults with a BMI of 30 or above) bringing the total titration range up further than when the medicine first launched. Whether a particular dose or pen format is available is confirmed at consultation; stock and availability vary.

Side effects: what is common, what is rare, and what needs urgent attention

The most frequently reported side effects are gastrointestinal: nausea, diarrhoea, constipation, bloating and indigestion. They are most noticeable in the first days after starting or after a dose step, and for the majority of people they ease considerably within one to two weeks. Eating smaller portions and avoiding high-fat or very rich foods during the early weeks makes a real difference. Common questions about Wegovy fat jabs address this in more detail.

More serious but less common concerns include gallbladder problems and, rarely, acute pancreatitis. The NHS semaglutide medicines page lists all known side effects clearly. Seek urgent medical help for severe, persistent stomach pain that spreads to your back, with or without vomiting, this warrants same-day attention. Suspected side effects can be reported to the MHRA via the Yellow Card scheme.

Wegovy carries a Black Triangle (▼) symbol, meaning the MHRA actively collects additional safety data. That is standard for newer medicines, not a signal of unusual danger. If you are taking oral contraceptives, your prescriber will advise on whether an additional method is needed during treatment. If surgery is planned, tell your anaesthetist you are taking a GLP-1 medicine. These are routine precautions, not reasons to avoid treatment, they are simply part of being looked after properly.

If questions come up once you have started treatment, our aftercare team is available seven days a week. When you are ready to find out whether Wegovy suits your situation, you can speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber.